Achilles Therapeutics UK Limited

2 trials Commercial sponsor

Filter these 2 trials by condition, phase, country and more.

Open in Search →

2 Registered trials

0 Recruiting

2 Completed trials

3 Countries active

3 Unique IMPs

100% Results reported

Phase I (FiH)

Phase I (FiH): 2

100%

2 of 2 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Large cell lung cancer stage III 1 Malignant melanoma of eyelid 1 Metastatic malignant melanoma 1 Non-small cell lung cancer recurrent 1 Non-small cell lung cancer stage IV 1 Adenosquamous cell lung cancer 1 Desmoplastic melanoma 1 Large cell lung cancer recurrent 1 Malignant melanoma 1 Melanoma recurrent 1 Non-small cell lung cancer metastatic 1 Non-small cell lung cancer stage IIIB 1

Top IMPs

ATL001 2 NIVOLUMAB 1 PEMBROLIZUMAB 1

All trials

2 total

A first-in-human clinical trial in adult patients with metastatic or recurrent melanoma of a personalised therapy targeting specific mutatio… Ended

2024-513062-19-00 Phase I (FiH) 1 country ATL001; NIVOLUMAB
A first-in-human clinical trial in adult patients with advanced non-small cell lung cancer of a personalised therapy targeting specific muta… Ended

2024-513060-26-00 Phase I (FiH) 3 countries ATL001; PEMBROLIZUMAB

Showing 1–2 of 2 trials

← All sponsors A–Z